The company plans to roll out additional specialty reagents to further accelerate research into microbial contamination and rapid detection strategies.
Invisible Sentinel CEO and co-founder Benjamin Pascal said the commercialization of the company's proprietary antibodies marks another important milestone for the company.
"We are currently seeking regulatory approval for our first-in-class diagnostic technology and anticipate commercialization of our diagnostic kits as early as this Fall," Pascal added.
Invisible Sentinel noted that it is primarily targeting the food industry, but its platform technology has the potential to provide valuable tools for additional industries including healthcare, veterinary, biodefense, and environmental testing.
Invisible Sentinel, based in Philadelphia, US, is a developer of rapid diagnostics for the detection of foodborne pathogens.
